Biobanks Market By Biobank Type (Population-based, Disease-specific, Commercial, Academic, Hospital, Public health, Distributed), By Sample Type (Blood, Tissues, Cells, Biofluids, Microbiome samples), By Storage (Cryogenic, Ultra-low freezers −80 °C, Refrigerated 2–8 °C, Stabilized kits, FFPE, Lyophilized), By Services Offered (Sample collection & processing, Long-term storage & retrieval, Quality control & biospecimen QC, Sequencing analysis, Bioinformatics & data analytics, Consent management & compliance), By Application (Drug discovery & development, Biomarker discovery & validation, Clinical trials & patient recruitment, Precision medicine, Epidemiology & population health, Regenerative medicine & diagnostics, Others), By End User (Pharmaceutical & biotech companies, Contract Research Organizations (CROs), Academic & research institutes, Hospitals & clinical centers, Diagnostic laboratories, Others), Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles And Market Forecast, 2025 – 2035.

---

What trends will shape the Biobanks Market in the coming years?

The Biobanks Market accounted for USD 82.03 Billion in 2024 and USD 88.63 Billion in 2025 is expected to reach USD 192.24 Billion by 2035, growing at a CAGR of around 8.05% between 2025 and 2035. The biobanks market will transform very fast, with a number of trends influencing the market in the years to come. The rise in demand for personalized medicine and precision oncology will drive the requirement for good-quality, highly annotated biospecimens. Recent progress in genomics, proteomics, and multi-omics integration will take biobanks far beyond sample storage in the provision of data. AI, big data analytics, and blockchain will improve sample traceability, interoperability, and insights into predictions.

Models of efficiency and minimizing errors will come in through automation and robotic storage systems. Increasing the focus on dynamic consent models will increase compliance with ethics and trust of the donors. An increase in population-based and disease-specific biobanks will drive epidemiological studies at scale. More pharma-CRO-academic partnerships will promote commercialization. Lastly, a decentralized and virtual model of biobanking will facilitate access to and sharing of data globally securely.

What do industry experts say about the Preclinical CRO market trends?

“Trends suggest that demand will not improve during the second half of the year as we had previously anticipated, and in fact, will decline for global biopharmaceutical clients.”

• James C. Foster, CEO of Charles River Laboratories.

“Throughout 2024, we have launched initiatives to generate more revenue, aggressively reduce costs, and further strengthen our business.”

• James C. Foster, CEO of Charles River Laboratories.

“We are very excited about the opportunity of working with Cinven. Medpace has generated significant growth recently in Europe, so it made huge sense for us to partner with a private equity sponsor with a strong European presence and the ability to help us expand our operations in Asia.”

• August Troendle, CEO of Medpace.

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Biobanks market?

How will rising personalized medicine adoption increase demand for high-quality biobank samples globally?

Personalized medicine is constantly gaining popularity in the world, which leads to a considerable development of the global biobanks market since it needs high-quality and diverse biological samples. Personalized medicine is based on the concept of therapy according to the patient-specific features, including genetic, proteomic, and metabolomic, which promotes the necessity of annotated biospecimens. Biobanks can play a crucial role as vital data storage facilities connecting biological samples with clinically rich information, allowing the discovery of biomarkers and the development of targeted therapy. With the continued growth of personalized medicine beyond genomics to multi-omics strategies, biobank resources are becoming more and more dependent upon researchers to learn about the complex disease mechanisms. Large biobank datasets are being analyzed with advanced computational tools, such as artificial intelligence and machine learning, to gain predictive information.

Accessibility and usefulness of biobank samples are enhanced by a combination of academic institutions and hospitals, and pharmaceutical companies in a partnership and cooperation scheme, which is referred to as the public-private partnership. Standardised protocols and quality control measures ensure reproducibility and reliability of the results of research across studies. Such initiatives as the Cancer Moonshot can be viewed as the value of shared biobank resources to accelerate translational research. Other aspects that biobanks are contributing towards advancing healthcare innovativeness are longitudinal studies, research in population health, and clinical trial recruitment.  As the U.S. National Institute of Standards and Technology indicated, the healthcare cost may be lowered due to personalized medicine, which may exclude undesired procedures and may enhance patient outcomes, and the strategic significance of research with biobanks is emphasized.

Can growing government and private research funding accelerate biobanking infrastructure and technological advancements worldwide?

On the world biobanks market, there is a rapid market expansion with more and more government and private funding of research infrastructure and technology. Grants are granted by public funding agencies, including the U.S. National Science Foundation, to create and improve infrastructure for biological research, including biobanks, to facilitate sample collection, storage, and data management. Advanced technologies, such as automation, artificial intelligence, and cloud-based data analytics to manage sample handling, are also supported by the involvement of the pharmaceutical companies and biotech firms, and philanthropic organizations in the private sector. More funding can enable new specialty biobanks to be developed to tackle rare diseases, population-oriented research, and precision medicine programs to increase the range of biospecimens stored.

Credit-public partnerships between government institutions and commercial organizations lead to standardization, quality assurance, and interoperable data-sharing systems, which ensure samples can be available to international research. These collaborations, as well, enable the integration of multi-omics data, which in turn aid in biomarker discovery, drug development, and research translation. Infrastructure upgrades funded result in long-term storage, such as ultra-low freezers and cryogenic and stabilized kits, which enhance the preservation of samples. The aspects of training and development of the workforce are encouraged so that skilled staff can operate the complicated biobanks. A combination of these investments contributes to faster innovation, reliability, and scalability in biobanking networks. Altogether, both government and non-government funding are essential forces, as they allow the biobanks market to contribute to the latest studies and healthcare innovations all over the world.

How might stringent data privacy regulations limit international sharing of biobank samples and information?

The biobanks market is under pressure, as the strict rules of data privacy can limit the cross-border sharing of samples and related data. The legislation known as GDPR in Europe and HIPAA in the United States has stringent requirements on the process of manipulating personal data, which include approval, anonymization, and safeguarding. Such rules have the ability to impede the international transfer of biospecimens because institutions will have to guarantee adherence to various national norms. Cross-border partnerships can encounter legal and ethical challenges in the transfer of patient-related data across borders. The variation in regulatory frameworks may also pose an inconvenience to a multi-center study by generating uncertainty for researchers who are interested in gaining access to global datasets.

Biobank operators are financially and operationally burdened with compliance costs such as data encryption, auditing, and legal oversight. Also, the rigorous requirements of consent might restrict the kind of analyses that are allowed on common samples, which hinders the flexibility of research. As much as patient privacy is paramount, these rules can negatively affect the rate and magnitude of scientific research in the world. Biobanks should also invest in a secure data platform and governance policies to enable safe international cooperation. Altogether, the compliance with the regulation determines the equilibrium between the ethical responsibility and utility maximization of the biobank's resources in the global arena.

How can emerging decentralized biobank networks enable broader global access and collaboration among researchers?

The biobanks market is recorded to be on a high growth trend, owing to the rising popularity of personalized medicine that needs access to high-quality and a variety of biological samples. Personalized medicine customizes care based on the specific traits of the patient, including genetic, proteomic, and metabolomic data, which is why well-annotated biospecimens are in demand. Biobanks are needed as repositories connecting biological specimens to rich clinical information and thus biomarker discovery and directed therapy generation. In the context of the growing trend toward multi-omics approaches to personalized medicine beyond genomics, biobank resources are becoming increasingly important to the mechanism of complex diseases. Predictive information is being extracted using advanced computational systems such as artificial intelligence and machine learning on large datasets of biobanks.

Biobank samples become more easily accessible and useful because of the collaboration and partnerships of the pharmaceutical companies, hospitals, and academic institutions. The rules and quality control measures make sure that the results of research are reproducible and reliable across studies. Such initiatives as the Cancer Moonshot provide an example of shared biobank resources in the rapid completion of translational research. Biobanks are also useful in longitudinal studies, population health studies, and the recruitment of clinical trials, extending their influence on health innovation. The U.S. National Institute of Standards and Technology notes that personalized medicine could help to save healthcare expenses by avoiding unnecessary procedures and enhancing patient outcomes, which is why biobank-driven research is naturally strategic.

Will partnerships with pharmaceutical companies drive the development of specialized disease-focused biobank repositories?

The pharmaceutical partnerships with academic institutions are driving the global biobanks market to grow significantly because they facilitate the creation of disease-specific repositories. These partnerships allow the sharing of resources, expertise, and patient-derived samples to accelerate the research on specific diseases. Biobanks that have received such alliances are often accompanied by highly established genomic, proteomic, and metabolomic technologies to aid in the collection and analysis of high-quality data. Such alliances enhance the biomarker discovery process, identification of therapeutic targets, and drug development by linking clinical data to biological samples. Industry involvement ensures that it uses standardised processes, quality management processes, and compliance with ethical and regulatory processes.

Disease-specific biobanks provide the researcher with access to rare or complex patient groups and permit increasingly specific research and personalised medicine initiatives. Public-privacy partnerships also facilitate infrastructure development, including but not limited to secure storage, automated sample handling, and data management systems. The collaborative networks enhance the availability of samples to multi-center trials and worldwide research programs. Translational research can be expedited through such partnerships, which reduce the gap between lab findings and clinical use. Altogether, pharmaceutical partnerships play a crucial role in the creation of specialized biobank depositories, the development of precision medicine, and better patient outcomes in the global arena.

What are the key market segments in the Biobanks industry?

Based on the biobank type, the Biobanks Market is classified into Population-based, Disease-specific, Commercial, Academic, Hospital, Public health, and Distributed. Population-based biobanks emphasize the use of very large cohorts of samples to facilitate epidemiology and genetic research. Specialized biobanks are specific to diseases, containing specimens pertinent to a specific disease, e.g., cancer, cardiovascular, or rare disease. The business model of commercial biobanks is based on profit generation and storage and access services to pharmaceutical and biotech firms. Universities or research institutions also tend to have academic biobanks, which assist with scientific investigations and clinical studies.

Hospital biobanks are collecting and handling patient-derived samples, usually combined with clinical workflows. Governments or health organizations create public health biobanks to be able to track population health trends. Distributed, virtual, or networked biobanks are biobanks that link many storage locations but offer central access. A combination of these types constitutes the backbone of the biobanking ecosystem in the world, and it facilitates improvements in diagnostics, therapeutics, and precision medicine.

Based on the application, the Biobanks Market is classified into Drug discovery & development, Biomarker discovery & validation, Clinical trials & patient recruitment, Precision medicine, Epidemiology & population health, Regenerative medicine & diagnostics, and Others. Biobank samples are used in drug discovery and drug development to discover drug targets and test potential drug candidates. The discovery and validation of biomarkers depend on high-quality specimens to come up with diagnostic or prognostic indicators applicable to different diseases. Biobanks are useful in clinical trials and patient recruitment because they make well-characterized samples and patient data available.

Precision medicine uses the resources of biobanks to match treatment on the basis of genetic, molecular, or phenotypic profiles. Large-scale samples are collected to gain insight into disease prevalence, risk factors, and health trends using epidemiology and population health studies. Biobank specimens are used in regenerative medicine and diagnostics in cell therapy, tissue engineering, and the development of novel diagnostic tools. The other uses are educational, translational research, and supporting emerging biotechnologies. Taken together, these applications underscore the importance of biobanks in furthering science and patient outcomes.

Which regions are leading the Biobanks market, and why?

The North America Biobanks Market is leading due to the availability of developed healthcare facilities and research organizations. The US is dominant because it has huge government- and privately funded biobanking programs, as well as high uptake of precision medicine and genomics research. Canada is no exception: population-based biobanks and community-based health programs that are oriented to the knowledge of genetic variation and disease prevalence play their role. The region also boasts of good regulatory measures that include the HIPAA and FDA measures, which are a source of assurance in quality, ethical standards, and data integrity.

Cloud-based systems of data management, automation, and artificial intelligence are increasingly penetrating biobanks in North America to improve their efficiency and analytical capabilities. There is also an augmentation of samples and research through the collaboration of academic institutes, hospitals, and pharmaceutical companies. Ongoing development of new storage solutions and high-throughput technologies contributes to scalability and long-term sustainability. On the whole, North America has been the center of innovation in biobanks, driving the trends internationally and establishing the standards in the industry.

The Asia Pacific Biobanks Market is leading due to the growing investment in their infrastructure and research capacity in the healthcare sector. The major drivers of the expansion are countries such as China, India, and Japan, which are undertaking government-subsidized programs and partnerships with other international drug manufacturing firms. The increasing interest in the understanding of precision medicine and population health is necessitating the need to have large-scale, well-annotated collections of biobanks. The area is also advantaged by increased academic and hospital-based biobanks to facilitate clinical trials and translational research.

The adoption of technologies such as automated storage, bioinformatics platforms, etc., is being adopted at high rates with an aim of improving sample management and analytics. Positive regulatory changes and policies that encourage biomedical research also enhance growth in the market. Also, enhancing involvement in research partnerships on the international level opens international expertise and resources. Overall, the dynamic nature of the Asian market makes it one of the major factors of biobank innovation and growth on a global scale.

What does the competitive landscape of the Biobanks market look like?

The Biobanks Market is highly competitive, with the top players in the market leading innovation and setting the trend in the industry, including Thermo Fisher Scientific, QIAGEN, Hamilton Company, Tecan Group Ltd., and Becton Dickinson. The companies are targeting the improvement of automation, AI implementation, and high data analytics to advance sample management, retrieval, and general operational efficiency. To achieve access to different biospecimens and aid in translational research, it is standard practice to work across different academic centers, hospitals, and pharmaceutical firms in a collaborative manner. Data sharing and multi-site collaboration and ethics. Virtual and distributed biobanks are transforming data sharing and allowing secure multi-location collaboration and ethics.

Regulations are also important, and businesses invest in the best quality control and data governance systems. Niche growth opportunities are being generated by specialized biobanks, including those of rare diseases or population-specific samples. A key UK biobank in April 2025 opened the anonymized health data of 500,000 patients to international researchers, demonstrating the potential of global data sharing. This progress reveals the importance of standards of ethics, control of consent, and data confidentiality in worldwide collaborations. The companies are consolidating their roles in the market through constant product innovation, strategic mergers, and technology. Overall, innovation, compliance with regulations, collaboration with partners abroad, and evolving research priorities affect the competitive environment and precondition the further evolution and shifts in the market.

Biobanks Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Biobanks industry?

• In June 2025, Cryptobiotix, a biotech company specializing in microbiome modeling with its SIFR platform, officially launched its internal biobank. The biobank securely stores cryopreserved human gut microbiome samples along with detailed donor metadata, accelerating experimentation workflows by enabling rapid, targeted access to samples for client research.

Report Coverage:

By Biobank Type

• Population-based
• Disease-specific
• Commercial
• Academic
• Hospital
• Public health
• Distributed

By Sample Type

• Blood
• Tissues
• Cells
• Biofluids
• Microbiome samples

By Storage

• Cryogenic
• Ultra-low freezers (−80 °C)
• Refrigerated (2–8 °C)
• Stabilized kits
• FFPE
• Lyophilized

By Services Offered

• Sample collection & processing
• Long-term storage & retrieval
• Quality control & biospecimen QC
• Sequencing analysis
• Bioinformatics & data analytics
• Consent management & compliance
• Public health agencies

By Application

• Drug discovery & development
• Biomarker discovery & validation
• Clinical trials & patient recruitment
• Precision medicine
• Epidemiology & population health
• Regenerative medicine & diagnostics
• Others

By End User

• Pharmaceutical & biotech companies
• Contract Research Organizations (CROs)
• Academic & research institutes
• Hospitals & clinical centers
• Diagnostic laboratories
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Thermo Fisher Scientific Inc.
• Merck KGaA, Darmstadt, Germany
• QIAGEN N.V.
• Hamilton Company
• Avantor, Inc.
• Beckton Dickinson (BD)
• BioLife Solutions Inc.
• Tecan Group Ltd.
• Stemcell Technologies Inc.
• Azenta Life Sciences
• Cryoport Inc.
• Bio-Techne Corporation
• Coriell Institute for Medical Research
• UK Biobank
• China Cord Blood Corporation

Frequently Asked Questions (FAQs)